July 07, 2017 07:00 ET | Source: NewLink Genetics Corporation

AMES, Iowa, July 07, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation(NASDAQ:NLNK), today announced that it will release its second quarter 2017 financial results onFriday, July 28, 2017. The company has scheduled a conference call for8:30 AM ETthe same day to discuss the results and to give an update on its clinical and development activities.

NewLink Genetics'senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.

Access to the live conference call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through theNewLink Geneticswebsite athttp://edge.media-server.com/m/p/mqa6eh65. A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 51432155.

AboutNewLink Genetics Corporation

NewLink Geneticsis a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.Indoximod is being evaluated in combination with treatment regimens including anti-PD-1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visithttp://www.newlinkgenetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements ofNewLink Geneticsthat involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements thatNewLink Geneticsmakes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere inNewLink Genetics'Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release representNewLink' Genetics'views as of the date of this press release.NewLink Geneticsanticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representingNewLink Genetics'views as of any date subsequent to the date of this press release.

Related Articles

NewLink Genetics Corporation

Ames, Iowa, UNITED STATES

http://www.linkp.com

NewLink Genetics Corporation Logo

LOGO URL | Copy the link below

Formats available:

Read more:
NewLink Genetics to Host Its Second Quarter 2017 Financial ... - GlobeNewswire (press release)